Planning Underway for Phase 3 Clinical Trial Testing Encapsulated Cell-Based Delivery of CNTF

Planning is underway for a Phase 3 clinical trial to test encapsulated cell-based delivery of Ciliary Neurotrophic Factor (CNTF) for the treatment of macular telangiectasia type 2.  The decision to run a Phase 3 clinical trial follows the announcement that a 24-month Phase 2 trial demonstrates that encapsulated cell-based therapy delivering CNTF has a beneficial effect in patients with macular telangiectasia type 2 (MacTel).

If you are interested in participating or would like more information, please contact us (info@lmri.net).  More details about the trial, and where to enroll, are expected in the fourth quarter of 2017.